Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer

NCT04965714 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 patient accrual

Conditions

Resectable Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Pegargiminase
PROCEDURE: Resection

Sponsor

M.D. Anderson Cancer Center